1. Cell Cycle/DNA Damage
  2. Deubiquitinase
  3. VLX1570

VLX1570 is a competitive inhibitor of proteasome deubiquitinases (DUBs) with an IC50 of approximate 10 μM.

For research use only. We do not sell to patients.

VLX1570 Chemical Structure

VLX1570 Chemical Structure

CAS No. : 1431280-51-1

Size Price Stock Quantity
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
USD 341 In-stock
Solution
10 mM * 1 mL in DMSO USD 341 In-stock
Solid
1 mg USD 130 In-stock
5 mg USD 330 In-stock
10 mg USD 520 In-stock
50 mg USD 1550 In-stock
100 mg USD 2400 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Top Publications Citing Use of Products

    VLX1570 purchased from MedChemExpress. Usage Cited in: Mol Cancer Ther. 2018 Jul;17(7):1416-1429.  [Abstract]

    VLX1570 blocks USP14, but not UCHL5, activity in melanoma.
    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    VLX1570 is a competitive inhibitor of proteasome deubiquitinases (DUBs) with an IC50 of approximate 10 μM.

    IC50 & Target

    IC50: appr 10 μM (Deubiquitinase)[2]

    In Vitro

    VLX1570 inhibits USP14 and UCHL5 activity of 19S regulatory particles, and the inhibition of USP14 is more pronounced. VLX1570 (1 μM) shows inhibitory activity against USP14 in KMS-11 myeloma cells. VLX1570 exhibits an IC50 of 0.58 μM on HCT116 cells[1]. VLX1570 binds to recombinant USP14 with Kd of 1.5-18 μM using two different sources of recombinant protein, and the Kd for recombinant UCHL5 is higher (14-18 μM) compared to that of USP14. VLX1570 has potent antiproliferative activities on multiple myeloma cells, with IC50s of 43 ± 2 nM, 74 ± 2 nM, 126 ± 3 nM, and 191 ± 1 nM for KMS-11, RPMI8226, OPM-2, and OPM-2-BZR cells, respectively[2]. VLX1570 suppresses the viability of BCWM.1 cells, with an EC50 of 20.22 nM. VLX1570 (100, 250, 500 nM) induces significant apoptosis by 12 h in a dose-dependent manner in all Waldenstrom macroglobulinemia (WM) cell lines tested, including BCWM.1/IR (IR) and BCWM.1/BR (BR) subclones. VLX1570 (100, 250, 500 nM) also causes ER stress machinery and mitochondrial damage in WM cells. VLX1570 (250 nM) downregulates BCR-signalosome components and their end effectors, as well as CXCR4 expression in WM cells[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    VLX1570 (3 mg/kg) significantly decreases tumor growth in mice bearing KMS-11 multiple myeloma cells[2]. VLX1570 (4.4 mg/kg, i.p.) markedly suppresses tumor growth, without obvious weight loss and other signs of systemic toxicity in the Waldenstrom macroglobulinemia (WM)-bearing mice[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    469.39

    Formula

    C23H17F2N3O6

    CAS No.
    Appearance

    Solid

    Color

    Light yellow to yellow

    SMILES

    O=C1/C(CN(C(C=C)=O)CC/C1=C\C2=CC=C(F)C([N+]([O-])=O)=C2)=C/C3=CC=C(F)C([N+]([O-])=O)=C3

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 32 mg/mL (68.17 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.1304 mL 10.6521 mL 21.3042 mL
    5 mM 0.4261 mL 2.1304 mL 4.2608 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    Purity & Documentation
    References
    Kinase Assay
    [1]

    Preparations of 26S proteasomes (1 nM) are pretreated with DMSO, VLX1570, or b-AP15 for 2 min in assay buffer (25 mM Tris, 5 mM MgCl2, 10% glycerol, 0.05 mg/mL BSA, 2 mM ATP, and 1 mM DTT) before addition of Ubrhodamine. Fluorescence is monitored at 37°C using Ex/Em = 490 nm/520 nm to read data every 10 second for 30 min using a TECAN infinite 200 instrument. For UbVS labeling of KMS 11 cells, cell pellets are lysed from control or treated cells with buffer (50 mM HEPES pH 7.4, 250 mM sucrose, 10 mM MgCl2, 2 mM ATP, 1 mM DTT) on ice for 30 min and removed debris by centrifugation. Twenty five μg of protein is labeled with 1 μM UbVS for 30 min at 37°C. Samples are resolved by SDS-PAGE and subjected to immunoblotting. For UbVS labeling of proteasomes, purified 19S proteasomes (50 nM) are pretreated with DMSO, VLX1570, or b-AP15 (50 μM) for 10 min at room temperature, followed by labeling with 1 μM HA-UbVS for 30 min at 37°C and by immunoblotting[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay
    [2]

    Cell viability is monitored by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. For the MTT assay, cells are suspended at 5 × 105 cells/mL, and 100 μL aliquots are dispended into 96-well microtiter plates and exposed to drugs using DMSO as control. At the end of incubations, 10 μL of a stock solution of 5 mg/mL MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), is added into each well, and the plates are incubated 4 hours at 37°C. Formazan crystals are dissolved with 100 μL of 10% SDS/10 mM HCl solution overnight at 37°C. Since MTT assays are affected by mitochondrial activity, and since OXPHOS is affected by VLX1570, the acid phosphatase method49 are used to determine cell viability in some experiments. After washing twice with PBS, cells are lysed in 100 μL of 0.1 M sodium acetate, 0,1% Triton X-100, p-nitrophenylphosphate and incubated for 90 min at 37°C. At the end of the incubation, 10 μL NaOH is added to each well and A405 is determined[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [3]

    Animal experiment is performed with a sample size of 7 per group, 80% power at the 5% significance level to detect a difference in means of 1800 mm3 between the 2 groups. For percentage change in IgM from baseline, with a sample size of 7 per group, 80% power at the 5% significance level is calculated to detect a difference in means of 450% between the 2 groups. Fourteen female NOD/SCID mice (6-8 weeks of age) are subcutaneously implanted with 1× 106 luciferase labeled RPCI-WM1 cells (Luc-RPCI-WM1), which are allowed to grow till a bioluminescent signal is observed by IVIS imaging (Day 20). On day 21, mice are randomized into 2 groups (n=7 each), with one group receiving vehicle (cremaphor+PEG+Tween) and the other receiving VLX1570 at 4.4 mg/kg via intraperitoneal injection. The investigator is not blinded to the group allocation. Both groups are respectively treated with either vehicle or VLX1570 every alternate day for 22 days. Sizes of the tumors is measured every 3- 4 days using direct caliper measurements, and volume of the tumorsis calculated using the formula (width)2 × length/2. Bioluminescent tumor imaging is performed with the Xenogen imaging system on Days 0, 20, 30, 36 and 43 post-tumor implantation. Blood from mice is collected on the same days by submandibular venous puncture, with sera subsequently separated for quantification of human IgM levels’ using ELISA. On Day 44, mice are sacrificed, and final tumor volume is measured in control and treatment arms. All images are obtained using a Canon D40 digital camera. No specific criteria for inclusion/exclusion are used as all mice formed tumors and are therefore included into the study[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.1304 mL 10.6521 mL 21.3042 mL 53.2606 mL
    5 mM 0.4261 mL 2.1304 mL 4.2608 mL 10.6521 mL
    10 mM 0.2130 mL 1.0652 mL 2.1304 mL 5.3261 mL
    15 mM 0.1420 mL 0.7101 mL 1.4203 mL 3.5507 mL
    20 mM 0.1065 mL 0.5326 mL 1.0652 mL 2.6630 mL
    25 mM 0.0852 mL 0.4261 mL 0.8522 mL 2.1304 mL
    30 mM 0.0710 mL 0.3551 mL 0.7101 mL 1.7754 mL
    40 mM 0.0533 mL 0.2663 mL 0.5326 mL 1.3315 mL
    50 mM 0.0426 mL 0.2130 mL 0.4261 mL 1.0652 mL
    60 mM 0.0355 mL 0.1775 mL 0.3551 mL 0.8877 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    VLX1570 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    VLX1570
    Cat. No.:
    HY-12471
    Quantity:
    MCE Japan Authorized Agent: